Merus N.V(NASDAQ:MRUS) 
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with...
Website: http://www.merus.nl
Founded: 2003
Full Time Employees: 87
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 40.69
H 40.69
L 36.47
C 38.11
V 1,233,382
10EMA 38.11
20EMA 38.11
60EMA 38.11
120EMA 38.11
250EMA 38.11